See more : Magnum Ventures Limited (MAGNUM.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Inovalon Holdings, Inc. (INOV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inovalon Holdings, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Autoliv, Inc. (ALIV-SDB.ST) Income Statement Analysis – Financial Results
- PVA TePla AG (0NL1.L) Income Statement Analysis – Financial Results
- AECI Ltd (AFE.JO) Income Statement Analysis – Financial Results
- Atomix Co.,Ltd. (4625.T) Income Statement Analysis – Financial Results
- Kringle Pharma, Inc. (4884.T) Income Statement Analysis – Financial Results
Inovalon Holdings, Inc. (INOV)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: http://www.inovalon.com
About Inovalon Holdings, Inc.
Inovalon Holdings, Inc. provides cloud-based platforms for data-driven healthcare. It operates Inovalon ONE Platform, a cloud-based platform that interconnect with the healthcare ecosystem to aggregate and analyze data in real-time, as well as empowers the application in resulting insights. The company also operates myABILITY software platform, an integrated set of cloud-based applications for providers that offers connectivity, administrative, clinical and quality analysis, management, and performance improvement capabilities to acute, post-acute, and ambulatory point-of-care provider facilities. In addition, it offers advisory, implementation, and support services. The company serves health plans and provider organizations, as well as pharmaceutical, medical device, and diagnostics companies. Its platforms include information of data pertaining to approximately 988,000 physicians; 522,000 clinical facilities; and approximately 314 million individuals and 53 billion medical events. Inovalon Holdings, Inc. was founded in 1998 and is headquartered in Bowie, Maryland.
Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 667.52M | 642.41M | 527.68M | 449.36M | 427.59M | 437.27M | 361.54M | 295.80M | 300.28M | 239.69M |
Cost of Revenue | 167.82M | 167.81M | 144.83M | 151.05M | 159.17M | 146.14M | 112.76M | 120.05M | 101.19M | 102.70M |
Gross Profit | 499.70M | 474.60M | 382.85M | 298.31M | 268.42M | 291.13M | 248.78M | 175.74M | 199.09M | 136.99M |
Gross Profit Ratio | 74.86% | 73.88% | 72.55% | 66.39% | 62.78% | 66.58% | 68.81% | 59.41% | 66.30% | 57.15% |
Research & Development | 33.50M | 33.69M | 28.64M | 27.38M | 29.15M | 22.33M | 23.13M | 21.19M | 15.50M | 14.86M |
General & Administrative | 216.62M | 200.76M | 205.04M | 149.95M | 137.28M | 115.03M | 88.57M | 80.64M | 72.66M | 63.18M |
Selling & Marketing | 62.94M | 62.41M | 45.53M | 34.10M | 27.08M | 14.68M | 7.14M | 5.95M | 6.79M | 6.75M |
SG&A | 279.56M | 263.17M | 250.57M | 184.05M | 164.35M | 129.71M | 95.71M | 86.59M | 79.45M | 69.94M |
Other Expenses | 114.93M | 108.25M | 96.73M | 53.09M | 37.28M | 22.63M | 19.88M | 15.52M | 12.90M | 11.23M |
Operating Expenses | 427.99M | 405.11M | 375.94M | 264.52M | 230.79M | 174.68M | 138.72M | 123.30M | 107.85M | 96.02M |
Cost & Expenses | 595.81M | 572.92M | 520.76M | 415.57M | 389.95M | 320.82M | 251.48M | 243.35M | 209.04M | 198.72M |
Interest Income | 479.00K | 2.24M | 2.18M | 5.43M | 5.79M | 3.00M | 6.00K | 9.00K | 11.00K | 10.00K |
Interest Expense | 56.18M | 65.83M | 50.90M | 6.23M | 5.07M | 4.42M | 1.34M | 79.00K | 129.00K | 62.00K |
Depreciation & Amortization | 114.93M | 108.25M | 96.73M | 53.09M | 37.28M | 22.63M | 19.88M | 15.52M | 12.90M | 11.23M |
EBITDA | 186.56M | 179.96M | 94.07M | 91.90M | 81.25M | 141.76M | 129.95M | 67.97M | 104.15M | 52.21M |
EBITDA Ratio | 27.95% | 28.01% | 17.83% | 20.45% | 19.00% | 32.42% | 35.94% | 22.98% | 34.68% | 21.78% |
Operating Income | 71.71M | 69.49M | 6.92M | 33.79M | 37.63M | 116.46M | 110.06M | 52.45M | 91.24M | 40.97M |
Operating Income Ratio | 10.74% | 10.82% | 1.31% | 7.52% | 8.80% | 26.63% | 30.44% | 17.73% | 30.38% | 17.09% |
Total Other Income/Expenses | -56.25M | -63.61M | -60.47M | -1.20M | 1.27M | -1.75M | -1.33M | -70.00K | -118.00K | -52.00K |
Income Before Tax | 15.46M | 5.88M | -53.56M | 32.59M | 38.90M | 114.71M | 108.73M | 52.38M | 91.12M | 40.92M |
Income Before Tax Ratio | 2.32% | 0.91% | -10.15% | 7.25% | 9.10% | 26.23% | 30.07% | 17.71% | 30.34% | 17.07% |
Income Tax Expense | -7.12M | -1.90M | -14.39M | -2.23M | 11.80M | 48.65M | 43.38M | 19.66M | 35.96M | 15.99M |
Net Income | 22.58M | 7.78M | -39.16M | 34.82M | 27.10M | 66.06M | 65.35M | 32.72M | 55.16M | 24.93M |
Net Income Ratio | 3.38% | 1.21% | -7.42% | 7.75% | 6.34% | 15.11% | 18.08% | 11.06% | 18.37% | 10.40% |
EPS | 0.15 | 0.05 | -0.27 | 0.24 | 0.18 | 0.45 | 0.53 | 1.47 | 2.48 | 1.12 |
EPS Diluted | 0.15 | 0.05 | -0.27 | 0.24 | 0.18 | 0.45 | 0.53 | 1.47 | 2.48 | 1.12 |
Weighted Avg Shares Out | 149.72M | 148.63M | 145.39M | 142.23M | 150.05M | 145.75M | 122.26M | 22.22M | 22.22M | 22.22M |
Weighted Avg Shares Out (Dil) | 149.72M | 148.63M | 145.39M | 142.74M | 150.96M | 148.28M | 122.26M | 22.22M | 22.22M | 22.22M |
Inovalon Recognizes Innovators Driving Healthcare Excellence with the 2024 Impact Awards
Inovalon's Payer Cloud Ranked #1 in 2024 By Black Book Research
Inovalon's Converged Quality Achieves 24th Consecutive NCQA HEDIS® Certification
Inovalon and MEDITECH Collaborate to Transform and Optimize Revenue Cycle
New Study From Inovalon and Genentech Finds Racial Disparities In Emergency Department Visits For Liver Cancer Care
AHF Files $50 Million Fraud Lawsuit Against Inovalon
Michael Hasbany, Former Inovalon Executive, Joins Healthmine's Advisory Board
Innovator Lists December Power Buffer ETF
Innovator Lists November Buffer ETF
Equity Consortium Led by Nordic Capital and Including Insight Partners Completes Acquisition of Inovalon
Source: https://incomestatements.info
Category: Stock Reports